Stockscreener 앱 받기
2.16
0.23%
-0.005
Biocardia Inc 주식(BCDA)의 최신 뉴스
Biocardia CEO Peter Altman acquires $221 in company stock - Investing.com
BioCardia to Participate in Fireside Chat at A.G.P. Virtual Heal - GuruFocus
BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025 - The Manila Times
BioCardia Reveals Latest Progress on Revolutionary Cell Therapy for Heart Failure at Major Healthcare Conference - Stock Titan
BioCardia, Inc. (NASDAQ:BCDA) Q1 2025 Earnings Call Transcript - Insider Monkey
BioCardia’s Earnings Call: Progress Amid Financial Strain - TipRanks
BioCardia Inc (BCDA) Q1 2025 Earnings Call Highlights: Progress in Cardiac Cell Therapy Amid ... - Yahoo Finance
BioCardia Reports Positive Q1 2025 Progress - TipRanks
Earnings call transcript: BioCardia’s Q1 2025 results show clinical progress - Investing.com
BioCardia Reports First Quarter 2025 Business Highlights and Financial Results - The Manila Times
BioCardia Reports Groundbreaking Heart Failure Trial Results: 82% Reduction in Angina Episodes - Stock Titan
BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025 - The Manila Times
BioCardia to Host Q1 2025 Corporate Update and Financial Results - GuruFocus
Insider Buying Surges in May. Especially These 5 Stocks - 24/7 Wall St.
BioCardia (BCDA) Expands Enrollment for Phase 3 CardiAMP HF II T - GuruFocus
BioCardia Advances Phase 3 CardiAMP HF II Trial - TipRanks
BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study - The Manila Times
First subject enrolled in BioCardia’s Phase III heart failure therapy trial - Yahoo
Form 8-KCurrent report - ADVFN
BioCardia Advances Cardiac Cell Therapy With Start Of Phase 3 CardiAMP HF II Trial - Nasdaq
BioCardia (BCDA) Moves Forward With Phase III CardiAMP HF II Tri - GuruFocus
BioCardia (BCDA) Moves Forward With Phase III CardiAMP HF II Trial | BCDA Stock News - GuruFocus
BioCardia Enrolls First Patient in Phase III Trial - TipRanks
BioCardia's Revolutionary Cell Therapy Enters Final Testing Phase for Heart Failure TreatmentKey Trial Details - Stock Titan
BioCardia (BCDA) Gains Attention Amid Surge in Search Activity | - GuruFocus
Biocardia CFO David McClung buys $24,999 in company stock By Investing.com - Investing.com Australia
Biocardia CFO David McClung buys $24,999 in company stock - Investing.com
BioCardia Executives Increase Their Stakes in the Company - TradingView
Biocardia CEO Peter Altman acquires $1,488 in stock - MSN
Beating Heart Patch Market Detailed In New Research Report 2025 | - openPR.com
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results - ADVFN
Biocardia CEO Peter Altman buys $214 in company stock By Investing.com - Investing.com South Africa
Biocardia CEO Peter Altman buys $214 in company stock - Investing.com Australia
DSMB recommends continuation of BioCardia’s cell therapy trial for heart failure - Yahoo
BioCardia’s CardiALLO-HF trial receives DSMB nod to proceed By Investing.com - Investing.com South Africa
BioCardia (BCDA) Receives Positive DSMB Recommendation for Cardi - GuruFocus
Biocardia Announces Positive Dsmb Review Of Cardiallo Allogeneic Cell Therapy For Heart Failure Phase 1/2 Clinical Trial - marketscreener.com
BioCardia’s CardiALLO Trial Advances After Safety Review - TipRanks
BioCardia’s CardiALLO-HF trial receives DSMB nod to proceed - Investing.com
BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic - GuruFocus
BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial - The Manila Times
Major Safety Milestone: Revolutionary Heart Failure Cell Therapy Advances to Next Phase - Stock Titan
1.89%
3.74%
자본화:
|
볼륨(24시간):